KR101507178B1 - 암 치료에 기여하는 방법, 조성물 및 제조품 - Google Patents

암 치료에 기여하는 방법, 조성물 및 제조품 Download PDF

Info

Publication number
KR101507178B1
KR101507178B1 KR1020097001590A KR20097001590A KR101507178B1 KR 101507178 B1 KR101507178 B1 KR 101507178B1 KR 1020097001590 A KR1020097001590 A KR 1020097001590A KR 20097001590 A KR20097001590 A KR 20097001590A KR 101507178 B1 KR101507178 B1 KR 101507178B1
Authority
KR
South Korea
Prior art keywords
tumor
irl1620
rats
paclitaxel
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097001590A
Other languages
English (en)
Korean (ko)
Other versions
KR20090034355A (ko
Inventor
아닐 굴라티
구루 레디
루이지 레나즈
Original Assignee
스펙트럼 파마슈티컬즈 인크
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스펙트럼 파마슈티컬즈 인크, 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 filed Critical 스펙트럼 파마슈티컬즈 인크
Publication of KR20090034355A publication Critical patent/KR20090034355A/ko
Application granted granted Critical
Publication of KR101507178B1 publication Critical patent/KR101507178B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020097001590A 2006-08-02 2007-07-20 암 치료에 기여하는 방법, 조성물 및 제조품 Active KR101507178B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/461,961 US20070032422A1 (en) 2002-10-24 2006-08-02 Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US11/461,961 2006-08-02
PCT/US2007/074036 WO2008016793A2 (en) 2006-08-02 2007-07-20 Methods, compositions and articles of manufacture for contributing to the treatment of cancers

Publications (2)

Publication Number Publication Date
KR20090034355A KR20090034355A (ko) 2009-04-07
KR101507178B1 true KR101507178B1 (ko) 2015-03-30

Family

ID=38752363

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001590A Active KR101507178B1 (ko) 2006-08-02 2007-07-20 암 치료에 기여하는 방법, 조성물 및 제조품

Country Status (17)

Country Link
US (4) US20070032422A1 (enExample)
EP (2) EP2046323B1 (enExample)
JP (1) JP2009545609A (enExample)
KR (1) KR101507178B1 (enExample)
CN (1) CN101522186B (enExample)
AR (1) AR062177A1 (enExample)
BR (1) BRPI0715521A2 (enExample)
CA (1) CA2658340C (enExample)
DK (1) DK2046323T3 (enExample)
ES (1) ES2402232T3 (enExample)
IL (1) IL196825A (enExample)
MX (1) MX2009001233A (enExample)
NO (1) NO20090915L (enExample)
RU (1) RU2407527C2 (enExample)
TW (1) TWI469776B (enExample)
WO (1) WO2008016793A2 (enExample)
ZA (1) ZA200900017B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
WO2008027839A1 (en) 2006-08-31 2008-03-06 Spectrum Pharmaceuticals, Inc. Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
CA2696398C (en) * 2007-08-21 2018-05-08 Midwestern University Methods for treatment of stroke or cerebrovascular accidents using an etb receptor agonist
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP3453390B1 (en) * 2016-05-06 2024-02-14 Biodynamic Research Foundation Polymerized drug-containing pharmaceutical composition
AU2024262867A1 (en) * 2023-04-26 2025-12-04 Biocells (Beijing) Biotech Co., Ltd. Polypeptide and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037235A2 (en) * 2002-10-24 2004-05-06 The Board Of Trustees Of The University Of Illinois Method and composition for preventing and treating solid tumors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
EP0799051B1 (en) 1994-12-12 2005-07-27 Omeros Corporation Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound
EP0815870A3 (en) 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition for prohylaxis or treatment of cerebral infarction
CA2268640A1 (en) 1998-04-14 1999-10-14 Mitsuru Shiraishi Composition for preventing or treating ischemic disease
WO2000018393A1 (en) 1998-09-25 2000-04-06 Warner-Lambert Company Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
WO2002049630A2 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
EP1819367B1 (en) 2004-11-22 2013-11-20 The Board Of Trustees Of The University Of Illinois Use of the endothelin etb receptor agonists irl-1620 in tumor imaging
CA2598439A1 (en) * 2005-02-22 2006-08-31 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
WO2008027839A1 (en) 2006-08-31 2008-03-06 Spectrum Pharmaceuticals, Inc. Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037235A2 (en) * 2002-10-24 2004-05-06 The Board Of Trustees Of The University Of Illinois Method and composition for preventing and treating solid tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Breast Cancer Research and Treatment, Vol. 94, pages 237-247 (2005) *
Breast Cancer Research and Treatment, Vol. 94, pages 237-247 (2005)*

Also Published As

Publication number Publication date
CA2658340C (en) 2015-11-24
CA2658340A1 (en) 2008-02-07
BRPI0715521A2 (pt) 2013-06-25
WO2008016793A2 (en) 2008-02-07
US8030278B2 (en) 2011-10-04
RU2009107085A (ru) 2010-09-10
JP2009545609A (ja) 2009-12-24
DK2046323T3 (da) 2013-04-22
EP2046323B1 (en) 2013-02-13
IL196825A (en) 2015-08-31
EP2450037A1 (en) 2012-05-09
TWI469776B (zh) 2015-01-21
US8729023B2 (en) 2014-05-20
WO2008016793A3 (en) 2008-07-31
KR20090034355A (ko) 2009-04-07
IL196825A0 (en) 2011-08-01
CN101522186A (zh) 2009-09-02
MX2009001233A (es) 2009-02-12
RU2407527C2 (ru) 2010-12-27
TW200820965A (en) 2008-05-16
NO20090915L (no) 2009-02-27
ZA200900017B (en) 2009-11-25
ES2402232T3 (es) 2013-04-30
US20130102543A1 (en) 2013-04-25
US8440620B2 (en) 2013-05-14
HK1129601A1 (en) 2009-12-04
AR062177A1 (es) 2008-10-22
US20070032422A1 (en) 2007-02-08
US20110315575A1 (en) 2011-12-29
US20090155206A1 (en) 2009-06-18
CN101522186B (zh) 2013-06-05
EP2046323A2 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
US8703709B2 (en) Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
KR101507178B1 (ko) 암 치료에 기여하는 방법, 조성물 및 제조품
JP2016528217A (ja) 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
JP2012214519A (ja) 固形腫瘍の治療に貢献するための方法、組成物及び製品
US8349802B2 (en) Methods and compositions for contributing to the treatment of cancers
JP5503528B2 (ja) 癌の処置に寄与する方法および組成物
AU2008240300B2 (en) Methods and compositions for contributing to the treatment of cancers
HK1129601B (en) Compositions for contributing to the treatment of cancers
HK1140145B (en) Compositions for contributing to the treatment of cancers

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120702

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131227

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140728

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131227

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20141028

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140728

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20150107

Appeal identifier: 2014101006700

Request date: 20141028

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20141127

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20141028

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140327

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20120702

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20150107

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20141216

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150324

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150324

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180309

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180309

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190313

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190313

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20200312

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20200312

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210316

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20220308

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240308

Start annual number: 10

End annual number: 10